Effect of 3 year Denosumab Treatment on Hip Structure in Japanese Postmenopausal Women and Men with Osteoporosis

Denosumab inhibits bone resorption by binding to and inactivating RANK ligand (RANKL), a key mediator of osteoclast formation, maturation and activation. As in the pivotal phase 3 study, FREEDOM, in predominantly postmenopausal Caucasian women with osteoporosis the efficacy of denosumab was evaluated by the phase 3 study, DIRECT, in Japanese osteoporosis patients. The study showed that 2-year treatment of denosumab significantly reduced risk of new vertebral fracture by 74.0% compared to placebo.

Source: Journal of Clinical Densitometry - October 1, 2018 Category: Radiology Authors: Teruki Sone, Naohiro Kon, Naoki Okubo, Masao Fukunaga, Masako Ito, Toshitaka Nakamura Source Type: research